Skip to main content
NRIX logo

NRIX · Nurix Therapeutics, Inc. · Executive Compensation

Track NRIX — free
$14.00 -0.10 (-0.71%)
Market Cap
$1.54B
Shares
109.25M
Volume · Nov 19 479.59K Avg daily vol (3M) 2.43M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Arthur T. Sands $6,374,138
Gwenn M. Hansen $2,498,124
Hans van Houte $2,296,503
Christine Ring $2,263,337
Fiscal 2024
Executive Total
Arthur T. Sands $5,812,862
Gwenn M. Hansen $2,033,860
Christine Ring $2,016,484
Hans van Houte $2,016,482
Fiscal 2023
Executive Total
Arthur T. Sands $4,363,120
Gwenn M. Hansen $1,632,757
Hans van Houte $1,611,987
Fiscal 2022
Executive Total
Arthur T. Sands $9,416,222
Hans van Houte $4,307,781
Gwenn M. Hansen $3,824,583
Fiscal 2021
Executive Total
Stefani A. Wolff $7,148,424
Arthur T. Sands $4,791,466
Gwenn M. Hansen $2,303,328
Hans van Houte $1,659,957
Christine Ring $1,648,895
Fiscal 2020
Executive Total
Arthur T. Sands $16,867,841
Gwenn M. Hansen $1,552,577
Christine Ring $1,307,091
Fiscal 2019
Executive Total
Arthur T. Sands $1,481,610
Gwenn M. Hansen $695,404

Executive changes

Person Change Filed
Roger Dansey, M.D. Appointed 2025-11-10
Roy D. Baynes, MB.Bch., M.Med., Ph.D. Appointed 2025-08-22
Lori A. Kunkel, M.D.
“Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2025-08-22
Lori A. Kunkel, M.D.
“Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2025-08-22
Roy D. Baynes, MB.Bch., M.Med., Ph.D. Appointed 2025-03-13
Anil Kapur Appointed 2024-10-16
Stefani A. Wolff Resigned 2023-04-10
Edward C. Saltzman Appointed 2022-09-14
Clay B. Siegall, Ph.D. Resigned 2022-05-16
Jeffrey K. Tong, Ph.D. Resigned 2022-03-07
Paul M. Silva Appointed 2021-09-30
Judith A. Reinsdorf Appointed 2021-09-30

Leadership

Key facts CIK 1549595 CUSIP 67080M103 13F (30d) 245 filings 228 filers Visit website Investor relations